Researchers identify CTLA-4 response marker
German and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1300 entries already.
Entries by Thomas Gabrielczyk
Inotrem SA raises 39m to provide POC for nangibotide
/in News/by Thomas GabrielczykFrench biotech Inotrem SA raised 39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Ermium Therapeutics bags 6.3m in Series A round
/in News/by Thomas GabrielczykParis-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Pharvaris BV raises $66m to advance oral HAE drug
/in News/by Thomas GabrielczykLeiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
4BIO Ventures launches US$50m fund
/in News/by Thomas GabrielczykLondon and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.
ADC Therapeutics set to go public
/in News/by Thomas GabrielczykAntibody drug conjugate expert ADC Therapeutics SA has filed a Registration Statement for an Initial Public Offering with the US Securities and Exchange Commission.
iStar Medical SA raises 40.1m
/in News/by Thomas GabrielczykGlucoma transplant specialist iStar Medical SA has closed a Series C finanincing round led by LSP and Gimv.
Pro-apoptotic protein blocks autoimmunity
/in News/by Thomas GabrielczykA US-EU research team has found that a class of compounds that promote tumour cell death can also limit autoimmunity.
Sequencing-ready DNA for fast Molecular Breeding results
/in News/by Thomas GabrielczykBioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. Their proprietary EchoLUTION single-step technology avoids the use of inhibitory process reagents while using dedicated […]
Immatics and Celgene enter $1.5bn deal
/in News/by Thomas GabrielczykCelgene will pay $75m upfront to get an option on three cancer programmes developed by Immatics Biotechnologies.